Back to top
more

Phibro Animal Health (PAHC)

(Delayed Data from NSDQ)

$26.59 USD

26.59
209,911

-0.55 (-2.03%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $26.75 +0.16 (0.60%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

QIAGEN (QGEN) Reports Preliminary Revenue Results for Q1

by Zacks Equity Research

Investors remain optimistic with QIAGEN's (QGEN) first-quarter 2020 preliminary revenue results, which is likely to benefit from increased testing demand for coronavirus infection.

Zacks Equity Research

Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View

by Zacks Equity Research

Investors remain optimistic on Illumina's (ILMN) strong preliminary revenue results for first-quarter 2020.

Zacks Equity Research

Here's Why You Should Add ResMed (RMD) in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and combatting the coronavirus outbreak.

Zacks Equity Research

Integra Releases Preliminary Q1 Results, Withdraws '20 View

by Zacks Equity Research

Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.

Zacks Equity Research

Medtronic (MDT) Demonstrates Global Growth Amid Cost Concerns

by Zacks Equity Research

Medtronic's (MDT) international Diabetes business registers solid growth on the continued adoption of MiniMed 670G in overseas markets.

Zacks Equity Research

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) on its strong segmental growth in the fourth quarter of 2019.

Zacks Equity Research

Product Launches Aid Hill-Rom Amid Project Timing Issues

by Zacks Equity Research

Hill-Rom (HRC) plans to roll out five-six new products each year through 2022.

Zacks Equity Research

Here's Why You Should Add STERIS (STE) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about STERIS (STE) on its strong segmental growth in the third quarter of 2020.

Zacks Equity Research

Haemonetics (HAE) Buys enicor to Expand Testing Portfolio

by Zacks Equity Research

Haemonetics (HAE) expands its portfolio with the buyout of enicor. With the latter's whole blood coagulation testing system, the company will address a wider range of criticalities in medicine.

Zacks Equity Research

Align Technology Buys exocad to Expand Its Digital Platform

by Zacks Equity Research

Align Technology (ALGN) expands its portfolio with the buyout completion of exocad. This will help the company offer fully integrated workflows to dental labs and dental practices worldwide.

Zacks Equity Research

IDEXX's (IDXX) CAG Arm Grows Strong on Product Launches

by Zacks Equity Research

Product launches like Cornerstone, Neo, Animana aid IDEXX' (IDXX) CAG business.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international growth in the fourth quarter of 2019.

Zacks Equity Research

Abbott (ABT) Rides on Point-of-Care Coronavirus Test Launch

by Zacks Equity Research

Abbott (ABT) launches a portable molecular point-of-care test to speed up coronavirus detection, especially in areas with severe outbreaks.

Zacks Equity Research

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) on its strong segmental results in the fourth quarter of 2019.

Zacks Equity Research

Baxter (BAX) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research

Baxter (BAX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

Here's Why You Should Add ResMed (RMD) in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) on its strong segmental and international results for the fiscal second quarter.

Zacks Equity Research

Why Is Phibro (PAHC) Down 7.9% Since Last Earnings Report?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

STERIS (STE) Stock Hits New 52-Week High: What's Driving it?

by Zacks Equity Research

STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with several tuck-in acquisitions.

Zacks Equity Research

Teleflex COMFORT FLO System's Voluntary Recall Ranked Class I

by Zacks Equity Research

Teleflex's (TFX) COMFORT FLO Humidification System up for worldwide voluntary recall after the receipt of complaints of device malfunction.

Zacks Equity Research

Medtronic Buys Digital Surgery, Boosts AI-Focus Surgical Care

by Zacks Equity Research

Medtronic (MDT) to integrate Digital Surgery's business within its Surgical Robotics arm, in turn augmenting the company's position in the field of surgical AI.

Zacks Equity Research

Omnicell-Geisinger Deal Improves Patient Care via Automation

by Zacks Equity Research

Omnicell's (OMCL) XT series Automated Dispensing Systems partners with Geisinger to streamline nursing workflow and improve patient care.

Zacks Equity Research

PRGO or PAHC: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PRGO vs. PAHC: Which Stock Is the Better Value Option?

Zacks Equity Research

Phibro (PAHC) Q2 Earnings Top Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Phibro (PAHC) witnessed revenue decline in two of its core segments and contraction in operating margin in Q2.

Zacks Equity Research

PRGO vs. PAHC: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PRGO vs. PAHC: Which Stock Is the Better Value Option?